JP2001512478A - 糖尿病のためのスルホニル尿素−グリタゾン相乗的組み合わせ物 - Google Patents

糖尿病のためのスルホニル尿素−グリタゾン相乗的組み合わせ物

Info

Publication number
JP2001512478A
JP2001512478A JP53661198A JP53661198A JP2001512478A JP 2001512478 A JP2001512478 A JP 2001512478A JP 53661198 A JP53661198 A JP 53661198A JP 53661198 A JP53661198 A JP 53661198A JP 2001512478 A JP2001512478 A JP 2001512478A
Authority
JP
Japan
Prior art keywords
patients
troglitazone
glyburide
treatment
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP53661198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001512478A5 (https=
Inventor
ホイットコウム，ランドル・ダブルユー
Original Assignee
ワーナー−ランバート・コンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ワーナー−ランバート・コンパニー filed Critical ワーナー−ランバート・コンパニー
Publication of JP2001512478A publication Critical patent/JP2001512478A/ja
Publication of JP2001512478A5 publication Critical patent/JP2001512478A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP53661198A 1997-02-19 1997-12-01 糖尿病のためのスルホニル尿素−グリタゾン相乗的組み合わせ物 Abandoned JP2001512478A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19
US60/038,224 1997-02-19
PCT/US1997/021996 WO1998036755A1 (en) 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergistic combinations for diabetes

Publications (2)

Publication Number Publication Date
JP2001512478A true JP2001512478A (ja) 2001-08-21
JP2001512478A5 JP2001512478A5 (https=) 2005-06-16

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53661198A Abandoned JP2001512478A (ja) 1997-02-19 1997-12-01 糖尿病のためのスルホニル尿素−グリタゾン相乗的組み合わせ物

Country Status (29)

Country Link
US (2) US5859037A (https=)
EP (1) EP0957923A1 (https=)
JP (1) JP2001512478A (https=)
KR (1) KR20000071179A (https=)
CN (1) CN1244801A (https=)
AR (1) AR011829A1 (https=)
AU (1) AU741215B2 (https=)
BG (1) BG103671A (https=)
BR (1) BR9714505A (https=)
CA (1) CA2272478A1 (https=)
CZ (1) CZ289299A3 (https=)
EA (1) EA199900725A1 (https=)
EE (1) EE9900345A (https=)
GT (1) GT199800037A (https=)
HN (1) HN1997000167A (https=)
HU (1) HUP0001528A3 (https=)
IL (1) IL130027A (https=)
IS (1) IS5058A (https=)
NO (1) NO993982D0 (https=)
NZ (1) NZ336002A (https=)
PA (1) PA8447401A1 (https=)
PE (1) PE74399A1 (https=)
PL (1) PL335166A1 (https=)
SK (1) SK111899A3 (https=)
SV (1) SV1998000010A (https=)
TR (1) TR199902033T2 (https=)
UY (1) UY24893A1 (https=)
WO (1) WO1998036755A1 (https=)
ZA (1) ZA981343B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126673A1 (ja) * 2005-05-27 2006-11-30 Daiichi Sankyo Company, Limited 組み合わせによる糖尿病治療薬
WO2008026668A1 (en) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Medicinal composition containing insulin resistance improving agent
WO2011059053A1 (ja) * 2009-11-13 2011-05-19 東レ株式会社 糖尿病の治療または予防薬

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
ATE355840T1 (de) * 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
KR20070011651A (ko) * 1997-06-18 2007-01-24 스미스클라인비이참피이엘시이 티아졸리딘디온 및 술포닐우레아를 사용한 당뇨병의 치료
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
KR100581199B1 (ko) 1998-06-19 2006-05-17 카이론 코포레이션 글리코겐 신타제 키나제 3의 억제제
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
IL143569A0 (en) * 1998-12-24 2002-04-21 Metabasis Therapeutics Inc A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
US6617122B1 (en) * 1999-03-15 2003-09-09 Xenon Genetics, Inc. Process for identifying modulators of ABC1 activity
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
PT1145717E (pt) * 2000-04-13 2004-08-31 Pfizer Prod Inc Efeito sinergistico de gliburide e milrinona
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20100137023A (ko) 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
MXPA06004639A (es) 2003-10-31 2006-06-27 Takeda Pharmaceutical Preparacion solida que comprende sensibilizador de insulina, secretagogo de insulina y ester de acidos grasos de polioxietileno sorbitano.
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
US20090286722A1 (en) * 2005-09-08 2009-11-19 Utech Limited Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
EP1943274A2 (en) * 2005-09-08 2008-07-16 Uutech Limited Treatment of diabetes related obesity
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
ZA200805147B (en) 2005-12-22 2010-05-26 Takeda Pharmaceutical Solid preparation
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
PT2868315T (pt) 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
WO2010065936A1 (en) * 2008-12-04 2010-06-10 Chongxi Yu High penetration compositions and their applications
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
WO2011146981A1 (en) 2010-05-24 2011-12-01 Ozstar Therapeutics Pty Ltd Anti-diabetic compositions and methods
KR102584819B1 (ko) 2011-01-19 2023-10-05 프랙틸 헬쓰, 인코포레이티드 조직의 치료를 위한 장치 및 방법
EP2782586A4 (en) * 2011-11-23 2015-07-01 Ozstar Therapeutics Pty Ltd ENHANCED SYNERGIC ANTIDIABETIC COMPOSITIONS
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
JP6167115B2 (ja) 2012-02-27 2017-07-19 フラクティル ラボラトリーズ インコーポレイテッド 組織の治療のための熱切除システム、デバイスおよび方法
KR102231179B1 (ko) 2012-04-19 2021-03-22 프랙틸 래브러토리스 인코포레이티드 조직 팽창 디바이스들, 시스템들, 및 방법들
EP2879605A4 (en) 2012-07-30 2016-04-06 Fractyl Lab Inc ELECTRICITY CONTROL SYSTEMS, DEVICES AND METHOD FOR TREATMENT OF TISSUE
WO2014026055A1 (en) 2012-08-09 2014-02-13 Fractyl Laboratories Inc. Ablation systems, devices and methods for the treatment of tissue
WO2014055997A1 (en) 2012-10-05 2014-04-10 Fractyl Laboratories Inc. Methods, systems and devices for performing multiple treatments on a patient
EP3003461B1 (en) 2013-06-04 2019-05-01 Fractyl Laboratories, Inc. Systems and devices for reducing the luminal surface area of the gastrointestinal tract
WO2015038973A1 (en) 2013-09-12 2015-03-19 Fractyl Laboratories, Inc. Systems, methods and devices for treatment of target tissue
KR102284469B1 (ko) 2013-11-22 2021-08-02 프랙틸 헬쓰, 인코포레이티드 위장관에 치료 제한부를 생성하기 위한 시스템, 장치 및 방법
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
EP3169260B1 (en) * 2014-07-16 2019-09-25 Fractyl Laboratories, Inc. System for treating diabetes and related diseases and disorders
US9757535B2 (en) 2014-07-16 2017-09-12 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
US12350264B2 (en) 2019-11-22 2025-07-08 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder
US12403138B2 (en) * 2019-11-22 2025-09-02 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
WO2021146535A1 (en) 2020-01-15 2021-07-22 Fractyl Laboratories, Inc. Automated tissue treatment devices, systems, and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126673A1 (ja) * 2005-05-27 2006-11-30 Daiichi Sankyo Company, Limited 組み合わせによる糖尿病治療薬
WO2008026668A1 (en) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Medicinal composition containing insulin resistance improving agent
WO2011059053A1 (ja) * 2009-11-13 2011-05-19 東レ株式会社 糖尿病の治療または予防薬
KR20120087987A (ko) * 2009-11-13 2012-08-07 고쿠리츠다이가쿠호우진 도쿄다이가쿠 당뇨병의 치료 또는 예방약
CN102655866A (zh) * 2009-11-13 2012-09-05 东丽株式会社 糖尿病的治疗或预防药
JP5697260B2 (ja) * 2009-11-13 2015-04-08 東レ株式会社 糖尿病の治療または予防薬
US9492422B2 (en) 2009-11-13 2016-11-15 Toray Industries, Inc. Therapeutic or prophylactic agent for diabetes
KR101701943B1 (ko) 2009-11-13 2017-02-02 도레이 카부시키가이샤 당뇨병의 치료 또는 예방약

Also Published As

Publication number Publication date
US5859037A (en) 1999-01-12
PE74399A1 (es) 1999-08-20
IL130027A (en) 2005-09-25
HN1997000167A (es) 1999-02-09
IL130027A0 (en) 2000-02-29
TR199902033T2 (xx) 2000-02-21
IS5058A (is) 1999-05-27
CZ289299A3 (cs) 1999-11-17
PL335166A1 (en) 2000-04-10
US5972973A (en) 1999-10-26
BR9714505A (pt) 2000-03-21
SV1998000010A (es) 1999-02-02
EP0957923A1 (en) 1999-11-24
ZA981343B (en) 1998-11-16
KR20000071179A (ko) 2000-11-25
UY24893A1 (es) 1998-07-10
EE9900345A (et) 2000-02-15
AU741215B2 (en) 2001-11-29
WO1998036755A1 (en) 1998-08-27
NO993982L (no) 1999-08-18
NZ336002A (en) 2002-03-28
AU5590898A (en) 1998-09-09
SK111899A3 (en) 2000-09-12
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28
EA199900725A1 (ru) 2000-04-24
HUP0001528A3 (en) 2000-12-28
CA2272478A1 (en) 1998-08-27
BG103671A (en) 2000-04-28
NO993982D0 (no) 1999-08-18
AR011829A1 (es) 2000-09-13
CN1244801A (zh) 2000-02-16
PA8447401A1 (es) 2001-12-14

Similar Documents

Publication Publication Date Title
JP2001512478A (ja) 糖尿病のためのスルホニル尿素−グリタゾン相乗的組み合わせ物
US6011049A (en) Combinations for diabetes
EP1097710B1 (en) Combination product for treating niddm
TWI278312B (en) Pharmaceutical composition for treating diabetes or a disease or condition associated with diabetes
JP2002543135A (ja) インスリン作用の増強方法
US20190134023A1 (en) Method of Restoring the Incretin Effect
US20050222262A1 (en) Novel NIDDM regimen
HUP0400964A2 (hu) (S)-2-Etoxi-3-[4-[2-[4-(metánszulfonil-oxi)-fenil]-etoxi]-fenil]-propánsavat vagy 3-[4-[2-[4-(terc-butoxi-karbonil-amino)-fenil]-etoxi]-fenil]-(S)-2-etoxi-propánsavat és inzulint tartalmazó gyógyszer-kombináció
WO2015017642A1 (en) Compositions and methods to treat the bihormonal disorder in diabetes
US20090227679A1 (en) Novel NIDDM Regimen
MXPA99007574A (en) Sulfonylurea-glitazone synergistic combinations for diabetes
Kuznar Clinical news updates from the 68th Scientific Sessions of the American Diabetes Association
HK1030872B (en) Novel niddm regimen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040924

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040924

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20071003